TACE Combined With ICIs Plus MTT After 125I Irradiation Stent Placement in HCC With Main PVTT.

Key facts

Sponsor

Zhongda Hospital

Principal Investigator

Gaojun Teng, M.D.

Zhongda Hospital

Enrollment

444 target

Eligibility

18 years · All sexes

Timeline

2024 – 2025

Study locations (1)

• Zhongda Hospital, Nanjing, Jiangsu, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Pediatric hepatocellular carcinoma

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT07295340
  Diagnostic Accuracy of Folate-Targeted NIR-II Carbon Dots for Ex Vivo HCC Detection
  West China Hospital
• RECRUITINGNANCT06050200
  TANGO-LIVER Three Arm Nuclear Growth Observation in Liver Surgery
  Medical University of Warsaw
• RECRUITINGPHASE1NCT04715191
  Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
  Baylor College of Medicine
• ACTIVE NOT RECRUITINGNANCT07214363
  The Safety and Efficacy of Irreversible Electroporation for the Treatment of Perivascular Liver Cancers
  National Taiwan University Hospital
• RECRUITINGNANCT05738980
  Prevention of Postoperative Recurrence of Hepatocellular Carcinoma by Blocking RAK Cells With Anti-TIM-3
  Beijing Hospital
• ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05120271
  BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors
  Sotio Biotech Inc.
• RECRUITINGNCT05517811
  Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection
  University of Colorado, Denver
• ACTIVE NOT RECRUITINGPHASE1NCT04377932
  Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
  Baylor College of Medicine

See all trials for Pediatric hepatocellular carcinoma →